<DOC>
	<DOCNO>NCT02263638</DOCNO>
	<brief_summary>Treatment refractory hemochromatosis rheumatism Anakinra . Prospective , multicenter , non-randomised , single-arm , open-label , phase II trial .</brief_summary>
	<brief_title>Treatment Refractory Hemochromatosis Rheumatism Anakinra : Preliminary Phase II Study</brief_title>
	<detailed_description>Hereditary hemochromatosis ( HH ) genetic disease characterize tissue iron overload . The common genotype homozygosity p.Cys282Tyr mutation HFE gene ( MIM 235200 ) . It serious disease lead life threaten complication cirrhosis , liver carcinoma , heart failure diabetes mellitus . Currently , complication prevent phlebotomy . Two-thirds patient complain joint symptom represent major cause impair quality life . Phlebotomies ineffective HH rheumatism patient ' quality life often alter life threaten complication prevent . Furthermore , significant high risk joint replacement surgery patient compare control ( X 9 ) . There currently approve treatment hemochromatosis rheumatism . As look like severe osteoarthritis , calcium pyrophosphate deposition disease ( CPDD ) chondrocalcinosis , symptomatic treatment employ analgesic ( type I II ) , non-steroidal anti-inflammatory drug colchicine case acute joint flare , corticosteroid intra-articular injection occasionally oral glucocorticoid . However case treatment remain ineffective lead true disability . Frequently , local inflammatory symptom . Interleukin 1ß ( IL1ß ) play key role pathogenesis crystal arthropathy ( CPDD gout ) . Anakinra ( IL-1Ra ) , drug approve France rheumatoid arthritis , test short series case control refractory gout , CPDD two patient HH rheumatism . The aim phase II study test efficacy anakinra patient hemochromatosis refractory joint pain . It also evaluate opportunity perform phase III trial . In absence available data evolution rheumatism treat anakinra population patient resistant standard therapy , investigator consider phase III trial would justifiable rate success insufficient .</detailed_description>
	<mesh_term>Hemochromatosis</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Patients age equal 18 year old , Patients prove hereditary hemochromatosis homozygosity C282Y mutation HFE gene , Patients rheumatism relate hemochromatosis , consider rheumatologist refractory usual treatment define persistent painful symptomatology despite treatment least one month level 2 analgesic ( weak opioids ) maximal dose , NSAID , colchicine , steroid injection combination treatment , Patients pain &gt; 40/100mm measure VAS ( pain last 48 hour ) , Effective contraception use treatment 48h last administration woman reproductive age , Patients give write informed consent . Other cause inflammatory rheumatism Rheumatoid Arthritis , Spondyloarthropathies , psoriatic arthritis , systemic disease , Ongoing treatment Methotrexate , Hydroxychloroquine , biologic immunosuppressive drug Malignant pathology , monoclonal gammopathy , Intolerance anakinra , Contraindications use anakinra : pregnancy breastfeeding , hypersensitivity excipients proteins E. coli , severe renal impairment ( creatinine clearance &lt; 30 ml / minute ) , neutropenia ( neutrophil count &lt; 1.5 x 109 / l ) , ongoing infection Patients follow protocol , Persons subject major legal protection ( safeguard justice , guardianship , trusteeship ) , person deprive liberty .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hereditary haemochromatosis</keyword>
	<keyword>rheumatism</keyword>
	<keyword>anakinra</keyword>
</DOC>